Related Experiment Video
Updated: Sep 18, 2025
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Minimally invasive axillary lymph node dissection versus conventional axillary lymph node dissection: a comparative
Zongyan Li1,2, Zuxiao Chen1,2, Lina Wei1,2
1Department of Breast Surgery, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, # No.26 Yuancun Erheng Road, Guangzhou, 510650, China.
Background:
This study aims to compare the short-term clinical efficacy of minimally invasive axillary lymph node dissection (MIAD) versus conventional axillary lymph node dissection (CAD) in the treatment of breast cancer with positive axillary lymph nodes.
Methods:
We performed a retrospective analysis of the clinical data of breast cancer patients who underwent MIAD and CAD in the Breast Surgery Department from January 2022 to August 2024. The primary outcomes assessed included surgical results, complications, post-operative upper limb function, and quality of life score for both groups.
Results:
This study enrolled 147 patients, with 71 undergoing MIAD (including 25 with endoscopic-assisted axillary lymph node dissection and 46 with robotic-assisted axillary lymph node dissection) and 76 undergoing CAD. Compared to CAD, the mean intraoperative blood loss in the MIAD was lower (5.63 ± 4.16 vs. 21.13 ± 6.81 ml, p < 0.001). Impressively, in patients with BMI ≥ 24 kg/m2, there was no statistical difference in operative time between the two groups. Furthermore, despite an overall increase of 9.39 min in surgical duration in MIAD (47.52 ± 8.95 vs. 39.09 ± 9.20 min, p < 0.001), its advantages include lower degree of post-operative pain, better post-operative shoulder joint range of motion, and DSAH and FACT-B + 4 score (112.90 ± 10.80 vs. 106.88 ± 11.11, p = 0.001). There was no statistically significant difference in the post-operative complications and initial oncological outcomes between the two groups.
Conclusions:
MIAD is a safe alternative to CAD, particularly for obese patients. It significantly reduces intraoperative blood loss while improving post-operative shoulder joint function and enhancing quality of life.
